Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Inclusion Criteria: * Age ≥ 18 years * Metastatic colorectal cancer * Progression on or following standard therapy, or no standard therapy (phase Ib). Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy regimens (phase II) * Written documentation of mutant or wild-type RAS * Life expectancy ≥ 3 months * ECOG performance status ≤ 2 Exclusion Criteria: Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other EGFR inhibitors * Previous treatment with MEK-inhibitors * History of severe infusion reactions to monoclonal antibodies. * Symptomatic or untreated leptomeningeal disease * Symptomatic brain metastasis * Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO and history of keratitis. * Acute or chronic pancreatitis * Clinically significant cardiac disease * Not adequate hematologic, renal and hepatic function